drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Replicating arenavirus-based therapeutic cancer vaccine (viral vector) encoding HPV16 E6/E7 designed to elicit HPV16-specific CD8+ T-cell responses; heterologous partner to HB-201 in an alternating prime-boost regimen.
nci_thesaurus_concept_id
C173149
nci_thesaurus_preferred_term
HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202
nci_thesaurus_definition
A cancer vaccine consisting of replication-attenuated arenavirus encoding the inactivated fusion protein of the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) serotype 16, with potential immunomodulating and antineoplastic activities. Upon administration, HPV 16 E6/E7-encoding arenavirus vaccine HB-202 induces expression of the E6/E7 proteins and stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.
drug_category
GENE THERAPY
drug_class
Vaccine
drug_delivery_route
Intravenous
drug_mechanism_of_action
Replicating arenavirus vector delivering genes encoding an inactivated HPV16 E6/E7 fusion protein to antigen-presenting cells, driving strong MHC I presentation and expansion of HPV16-specific CD8+ cytotoxic T cells that recognize and kill HPV16 E6/E7–expressing tumor cells; used in a heterologous prime–boost with HB-201 to mitigate anti-vector immunity.
drug_name
HB-202
nct_id_drug_ref
NCT05108870